China SXT Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Cash & Equivalents	21.17	18.1	12.07	17.37	15.52	13.33
Cash & Short-Term Investments	21.17	18.1	12.07	17.37	15.52	13.33
Cash Growth	14.33%	49.95%	-30.50%	11.88%	16.43%	82.97%
Accounts Receivable	1.34	1.3	1.31	1.34	3.33	4.51
Other Receivables	1.36	0.42	-	-	1.62	1.58
Total Trade Receivables	2.7	1.72	1.31	1.34	4.95	6.09
Inventory	0.75	0.83	0.79	0.53	1.02	0.86
Other Current Assets	1.42	0.65	0.05	0.28	0.96	2.95
Total Current Assets	26.04	21.3	14.23	19.52	22.45	23.23
Net Property, Plant & Equipment	0.3	0.36	0.56	1.27	1.59	1.79
Other Intangible Assets	0.01	0.01	0.02	0.03	0.04	0.05
Other Long-Term Assets	-	-	8.31	8.74	9.46	9.48
Total Assets	26.35	21.66	23.13	29.55	33.55	34.55
Accounts Payable	0.53	1.16	2.33	6.58	10.18	13.6
Accrued Expenses	3.27	2.94	2.77	3.14	3.53	3.05
Short-Term Debt	0.98	0.7	2.27	3.32	2.03	-
Current Portion of Long-Term Debt	0	0.01	0.02	0.01	0.01	0.04
Current Portion of Leases	0.06	0.06	0.06	0.06	-	-
Unearned Revenue	0.07	0.06	0.19	0.17	0.08	0.26
Other Current Liabilities	1.05	1.09	1.27	1.22	1.29	1.63
Total Current Liabilities	5.96	6.01	8.9	14.5	17.12	18.58
Long-Term Debt	0.07	0.1	0.12	0.12	-	0.01
Long-Term Leases	0.09	0.12	0.18	0.25	-	-
Total Long-Term Liabilities	0.16	0.21	0.29	0.37	-	0.01
Total Liabilities	6.12	6.22	9.2	14.86	17.12	18.59
Common Stock	55.38	44.53	39.67	0.91	0.16	0.06
Additional Paid-in Capital	-	-	-	35.59	30.99	25.32
Accumulated Other Comprehensive Income	-0.77	-1.08	-1.03	-0.2	0.96	0.53
Retained Earnings	-34.38	-28.02	-24.71	-21.61	-15.69	-9.95
Shareholders' Equity	20.23	15.44	13.93	14.69	16.42	15.96
Total Liabilities & Equity	26.35	21.66	23.13	29.55	33.55	34.55
Total Debt	1.2	0.98	2.65	3.76	2.05	0.04
Net Cash (Debt)	19.96	17.12	9.42	13.61	13.48	13.29
Net Cash Growth	16.64%	81.63%	-30.77%	0.99%	1.42%	2259.84%
Net Cash Per Share	0.17	12.03	86.91	407.88	2592.48	3693.87
Book Value	20.23	15.44	13.93	14.69	16.42	15.96
Book Value Per Share	0.17	10.85	128.48	440.23	3159.28	4436.50
Tangible Book Value	20.23	15.43	13.91	14.66	16.39	15.92
Tangible Book Value Per Share	0.17	10.84	128.30	439.39	3151.83	4423.77

SEC Filings: 10-K · 10-Q